Viatris Inc. VTRS
This picture changes. Follow Viatris Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Viatris Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 31 Jul 2026
Latest news check: 7 Aug 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Existing position can be maintained pending Q2 report and regulatory milestones.
Strong Q2 execution and raised guidance are balanced against quantified supply risks and China uncertainty, supporting the hold signal.
Market sentiment
7/10
↑
Trend: Improving
Sentiment is mixed after a strong report but tempered by supply-chain concerns and China regulatory risks.
Price context
The stock trades near its 52-week high at 17.65 USD following a strong yearly recovery. Much of the rebound appears already priced in.
Risk assessment
6/10
Dilution:
Low
Strong cash flow and focus on buybacks
Jurisdiction:
Medium
Global operations with China exposure
Execution:
High
Pipeline dependence and history of delays
Recent changes
- Report shows raised full-year guidance after strong execution but driven by India production disruptions impacting H2.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Viatris is a global pharmaceutical company that develops, manufactures and sells generics, biosimilars and established branded medicines. The company is transitioning toward higher-margin complex products and pipeline launches in women's health, CNS and immunology.
Sector:
Pharmaceuticals, generics and branded medicines
Type:
Producer
Next report
5 Nov 2026
Q3
Catalysts
5 Nov 2026
FDA decision Meloxicam
High
27 Dec 2026
Gwyn Lo launch
High
Aug 2026
Q3 report
High
Horizon:
Bull case
Raised full-year outlook, margin expansion and upcoming pipeline launches provide operational momentum.
Bear case
India production issues and new hospital procurement rules in China create uncertainty for the second half.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| FDA decisions on new products | Rejection or delay → lower revenue growth from pipeline and weaker growth narrative. | Approval → higher share of high-margin products and improved profitability. |
| Debt reduction pace | Slower amortization → continued high interest costs and limited flexibility. | Faster reduction → lower risk and room for dividends or buybacks. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong Q2 execution and raised guidance are balanced against quantified supply risks and China uncertainty, supporting the hold signal.
Recent news
- Viatris released its Q2 report on August 6 with revenue of 3.76 billion USD and raised full-year guidance. The company sold global rights to Tyrvaya for up to 100 million USD and declared a dividend. Production disruptions in India are expected to cause 100–150 million USD revenue loss in H2.
Key figures
Revenue
Q2 2026
USD 3.8B
Revenue TTM
TTM
USD 14.3B
EBITDA
Q2 2026
USD 1.2B
Net income
Q2 2026
USD -119M
Total debt
Q1 2026
USD 14.5B
Gross margin
Q2 2026
57.5%
Shares outstanding
2026-05-04
1.2B
EPS
Q2 2026
USD -0.10
Price & valuation
Last close
USD 16.28
Market Cap
USD 19.0B
1 week
-7.8 %
3 months
-6.3 %
12 months
+60.9 %
From 52w high
-8.8 %
From 52w low
+71.5 %
Exchange
NASDAQ
Type
Producer
Sector
Pharmaceuticals, generics and branded medicines
This picture changes. Follow Viatris Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.